Literature DB >> 28790105

Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.

Marina Lafage-Pochitaloff1,2, Laurence Baranger2,3, Mathilde Hunault4, Wendy Cuccuini2,5, Christine Lefebvre2,6, Audrey Bidet2,7, Isabelle Tigaud2,8, Virginie Eclache2,9, Eric Delabesse10, Chrystèle Bilhou-Nabéra2,11, Christine Terré2,12, Elise Chapiro2,13, Nathalie Gachard2,14, Marie-Joelle Mozziconacci2,15, Geneviève Ameye16, Sarah Porter17, Nathalie Grardel18, Marie C Béné19, Yves Chalandon20,21, Carlos Graux22, Françoise Huguet23, Véronique Lhéritier24, Norbert Ifrah4, Hervé Dombret25.   

Abstract

Multiple cytogenetic subgroups have been described in adult Philadelphia chromosome (Ph)-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL), often comprising small numbers of patients. In this study, we aimed to reassess the prognostic value of cytogenetic abnormalities in a large series of 617 adult patients with Ph-negative BCP-ALL (median age, 38 years), treated in the intensified Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)-2003/2005 trials. Combined data from karyotype, DNA index, fluorescence in situ hybridization, and polymerase chain reaction screening for relevant abnormalities were centrally reviewed and were informative in 542 cases (88%), allowing classification in 10 exclusive primary cytogenetic subgroups and in secondary subgroups, including complex and monosomal karyotypes. Prognostic analyses focused on cumulative incidence of failure (including primary refractoriness and relapse), event-free survival, and overall survival. Only 2 subgroups, namely t(4;11)/KMT2A-AFF1 and 14q32/IGH translocations, displayed a significantly worse outcome in this context, still observed after adjustment for age and after censoring patients who received allogeneic stem cell transplantation (SCT) in first remission at SCT time. A worse outcome was also observed in patients with low hypodiploidy/near triploidy, but this was likely related to their higher age and worse tolerance to therapy. The other cytogenetic abnormalities, including complex and monosomal karyotypes, had no prognostic value in these intensive protocols designed for adult patients up to the age of 60 years.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2017        PMID: 28790105     DOI: 10.1182/blood-2017-05-783852

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

Review 1.  Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts.

Authors:  Nicholas J Short; Elias Jabbour; Maher Albitar; Marcos de Lima; Lia Gore; Jeffrey Jorgensen; Aaron C Logan; Jae Park; Farhad Ravandi; Bijal Shah; Jerald Radich; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2018-11-26       Impact factor: 10.047

2.  Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia.

Authors:  Yorleny Vicioso; Hermann Gram; Rose Beck; Abhishek Asthana; Keman Zhang; Derek P Wong; John Letterio; Reshmi Parameswaran
Journal:  Cancer Immunol Res       Date:  2019-05-28       Impact factor: 11.151

Review 3.  Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.

Authors:  Christopher Wenzinger; Eli Williams; Alejandro A Gru
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

Review 4.  Recent Advances in Adult Acute Lymphoblastic Leukemia.

Authors:  Guillaume Richard-Carpentier; Hagop Kantarjian; Elias Jabbour
Journal:  Curr Hematol Malig Rep       Date:  2019-04       Impact factor: 3.952

5.  Cytogenetic aberrations in adult acute lymphoblastic leukemia-A population-based study.

Authors:  Emma Bergfelt Lennmyr; Marie Engvall; Gisela Barbany; Linda Fogelstrand; Hanna Rhodin; Helene Hallböök
Journal:  EJHaem       Date:  2021-09-22

Review 6.  The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).

Authors:  F Nguyen-Khac; A Bidet; A Daudignon; M Lafage-Pochitaloff; G Ameye; C Bilhou-Nabéra; E Chapiro; M A Collonge-Rame; W Cuccuini; N Douet-Guilbert; V Eclache; I Luquet; L Michaux; N Nadal; D Penther; B Quilichini; C Terre; C Lefebvre; M-B Troadec; L Véronèse
Journal:  Leukemia       Date:  2022-04-16       Impact factor: 12.883

7.  Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT.

Authors:  Sebastian Giebel; Myriam Labopin; Gerard Socié; David Beauvais; Stefan Klein; Eva Maria Wagner-Drouet; Didier Blaise; Stephanie Nguyen-Quoc; Jean Henri Bourhis; Anne Thiebaut; Hélène Labussière-Wallet; Amandine Charbonnier; Ana Berceanu; José Luis Diez-Martin; Nathalie Fegueux; Jordi Esteve; Arnon Nagler; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2020-11-25       Impact factor: 5.483

Review 8.  MRD-Based Therapeutic Decisions in Genetically Defined Subsets of Adolescents and Young Adult Philadelphia-Negative ALL.

Authors:  Manuela Tosi; Orietta Spinelli; Matteo Leoncin; Roberta Cavagna; Chiara Pavoni; Federico Lussana; Tamara Intermesoli; Luca Frison; Giulia Perali; Francesca Carobolante; Piera Viero; Cristina Skert; Alessandro Rambaldi; Renato Bassan
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

9.  Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience.

Authors:  Guillaume Richard-Carpentier; Hagop M Kantarjian; Guilin Tang; C Cameron Yin; Joseph D Khoury; Ghayas C Issa; Fadi Haddad; Nitin Jain; Farhad Ravandi; Nicholas J Short; Courtney D DiNardo; Koichi Takahashi; Marina Y Konopleva; Naval G Daver; Tapan Kadia; Guillermo Garcia-Manero; Rebecca Garris; Susan O'Brien; Elias Jabbour
Journal:  Blood Adv       Date:  2021-12-14

10.  Fluorescence in situ hybridization comparison of the prognostic factors in adult and pediatric acute lymphoblastic leukemia: A retrospective analysis of 282 cases.

Authors:  Pengfei Cao; Yalan Yu; Wei Wang; He Xu; Yuxiang He
Journal:  Exp Ther Med       Date:  2018-10-02       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.